Sanofi, Regeneron Seem Keen to Keep Working Together
Dow Jones08-07 22:06
1406 GMT - Drugmakers Sanofi and Regeneron Pharmaceuticals seem to be exploring ways to work more strategically together again, Jefferies analysts say in a research note. They could work on extending the lifecycle of their blockbuster drug Dupixent or on next-generation immunology assets, even though neither company disclosed a new collaboration in recent earnings calls, the analysts say. The tone from executives at both Sanofi and Regeneron seemed to shift from their somewhat transactional relationship over the last few years, Jefferies says. Sanofi shares rise 2%, Regeneron's are little changed.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments